Art. -Nr.: HY-D0819

CY5-SE

(Synonyms: Cy5 NHS Ester; Sulfo-Cyanine5 Succinimidyl Ester)

45 Cited Publications

Kundenbewertung

Based on 45 publication(s) in Google Scholar

Cy5-SE (Cy5 NHS Ester) is a reactive dye for the labeling of amino-groups in peptides, proteins, and oligonucleotides. This dye requires small amount of organic co-solvent (such as DMF or DMSO) to be used in labeling reaction. This reagent is ideal for very cost-efficient labeling of soluble proteins, as well as all kinds of peptides and oligonucleotides. This reagent also works well in organic solvents for small molecule labeling. Excitation (nm):649, Emission (nm): 670.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.0%
CAS. Nr.: 146368-14-1
Formel: C₃₇H₄₃N₃O₁₀S₂
Molecular Weight:753.88

Speicherung:

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

CY5-SE Chemical Structure

CAS. Nr.: 146368-14-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- Emission (Em)
- Excitation (Ex)
- Dyeing Example
Chemical Information
Publications (45)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

Guide (The following is our recommended protocol. This protocol is only a guide and should be modified according to your specific needs).
1. Protein Preparation
To obtain the best labeling effect, please prepare the protein (antibody) concentration to 2 mg/mL.
1.1 The pH value of the protein solution should be 8.5 ± 0.5. If the pH is lower than 8.0, adjust it with 1 M sodium bicarbonate.
1.2 If the protein concentration is lower than 2 mg/mL, the labeling efficiency will be greatly reduced. To obtain the best labeling efficiency, it is recommended that the final protein concentration range be 2-10 mg/mL.
1.3 The protein must be in a buffer free of primary amines (such as Tris or glycine) and ammonium ions, otherwise the labeling efficiency will be affected.
2. Dye Preparation
Dilute the dye with anhydrous DMSO to prepare a clear stock solution of 10 mg/mL.
3. Calculation of Dye Amount
The amount of dye required for the reaction depends on the amount of protein to be labeled. The optimal molar ratio of dye to protein is approximately 10:1.
Example: Assuming the required labeled protein is 500 μL 2 mg/mL IgG (MW=150,000), and 1 mg of dye is dissolved in 100 μL DMSO, the required dye volume is 5.1 μL. The detailed calculation process is as follows:
1) mmol (IgG) = mg/mL (IgG) × mL (IgG)/MW (IgG) = 2 mg/mL × 0.5 mL/150,000 mg/mmol = 6.7 × 10^-6 mmol
2) mmol (dye) = mmol (IgG) × 10 = 6.7 × 10^-6 mmol × 10 = 6.7 × 10^-5 mmol
3) μL (dye) = mmol (dye) × MW (dye)/mg/μL (dye) = 6.7 ×10^-5 mmol ×753.88 mg/mmol/0.01 mg/μL = 5.1 μL (dye)
Note: We recommend using a dye:protein molar ratio of 10:1. If the concentration is too low or too high, the ratio can be adjusted to 5:1, 15:1, or 20:1.
4. Running the Coupling Reaction
1) Slowly add the calculated volume of freshly prepared 10 mg/mL dye to 0.5 mL of protein sample solution, gently shake to mix, and then briefly centrifuge to collect the sample at the bottom of the reaction tube. Avoid vigorous mixing to prevent denaturation and inactivation of the protein sample.
2) Place the reaction tube in a dark place and incubate gently with shaking for 60 minutes at room temperature. Every 10-15 minutes, gently invert the reaction tube several times to thoroughly mix the reactants and improve labeling efficiency.
5. Purification of Conjugates
The following protocol is an example of purifying dye-protein conjugates using a Labelling Kits Centrifugation-Based Rapid Desalting Column (5KD) (HY-D3014).
5.1 Prepare the desalting column according to the instructions.
5.2 Load the reaction mixture onto the top of the desalting column.
5.3 Once the sample has run below the resin surface, immediately add PBS (pH 7.2-7.4).
5.4 Add more PBS (pH 7.2-7.4) to the target sample to complete column purification. Collect the fraction containing the desired dye-protein conjugate.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Emission (Em)

670

Excitation (Ex)

633

Dyeing Example

Chemical Information

CAS. Nr. 146368-14-1
Appearance Solid
Molecular Weight 753.88
Formel C₃₇H₄₃N₃O₁₀S₂
Color Dark purple to black
SMILES

CC(/C(N1CCCCCC(ON2C(CCC2=O)=O)=O)=C\C=C\C=C\C3=[N+](CC)C(C=CC(S(=O)([O-])=O)=C4)=C4C3(C)C)(C)C5=C1C=CC(S(=O)(O)=O)=C5
Synonyms

Cy5 NHS Ester; Sulfo-Cyanine5 Succinimidyl Ester
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (45)

All Bio/Physico-chemical AssayCell Imaging/StainingFlow CytometryIn Vivo Imaging

Sort by:

Journal Impact Factor

Adv Mater

Homogeneous "Hard-Soft" Biphasic Bone Adhesives Promote Comminuted Fracture Healing through Interfacial Adaptation and Mechanical Property Maintenance. [Abstract]

2025 Jun 13:e2502598. PMID: 40511692

CY5-SE purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jun 13:e2502598. [Abstract]

CY5-SE (4mg; 12 h). Fluorescence labeling images of soft and hard phase distribution in HB-PTN hydrogels. Green and red represent the hard and soft phases, respectively.
Cell Mol Immunol

Oncolytic virus M1 reinvigorates CD8+ T-cell immunity against glioblastoma through B-cell-dependent antigen cross-presentation in the spleen. [Abstract]

2026 Apr;23(4):349-366. PMID: 41781696
Adv Funct Mater

2023 Sep 15.
ACS Nano

Dual-Powered Nanomotor In Situ Vaccine with Tumor-Confined Penetration and Acidity Neutralization Boosts Stimulator of Interferon Genes-Mediated Immunotherapy. [Abstract]

2026 Jan 20;20(2):2018-2033. PMID: 41486956
ACS Nano

Layered-Responsive Multivalent Tetrahedral DNA Framework-Decorated CRISPR-Cas12a Nanocapsule Enables Precise and Enhanced Tumor Chemotherapy. [Abstract]

2025 May 27;19(20):19274-19286. PMID: 40366179
ACS Nano

Negatively Charged Carbon Dots Employed Symplastic and Apoplastic Pathways to Enable Better Plant Delivery than Positively Charged Carbon Dots. [Abstract]

2024 Aug 27;18(34):23154-23167. PMID: 39140713
J Nanobiotechnology

Catalase-encapsulated matrix metalloproteinase-9 responsive nanogels for modulation of inflammatory response and treatment of neutrophilic asthma. [Abstract]

2025 May 24;23(1):374. PMID: 40410884
J Nanobiotechnology

Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization. [Abstract]

2024 Sep 19;22(1):578. PMID: 39300463

CY5-SE purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Sep 19;22(1):578. [Abstract]

The uptake efficiency of Cy5 NHS Ester (4 h)-loaded 2-APB@DGP or Cy5-loaded 2-APB@DGP-MM in BMDMs .
J Nanobiotechnology

An efficient antimicrobial depot for infectious site-targeted chemo-photothermal therapy. [Abstract]

2018 Mar 16;16(1):23. PMID: 29548342
Adv Sci (Weinh)

Protein Disulfide Isomerase Disassembles TDP-43/G3BP1 Condensates and Antagonizes TDP-43 Pathological Aggregates. [Abstract]

2026 Jul;13(38):e16846. PMID: 42178983
Adv Sci (Weinh)

2026 Apr 20.
Adv Sci (Weinh)

Regulating Tumor Metabolic Reprogramming with Biomimetic Co-Delivery of Simvastatin and Kynureninase for Immunotherapy. [Abstract]

2025 Dec 23:e08107. PMID: 41432057
Adv Sci (Weinh)

A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I-Labeled Tinurilimab. [Abstract]

2025 Apr 3:e2415689. PMID: 40178153
Adv Sci (Weinh)

Sulfated Polysaccharide Regulates the Homing of HSPCs in a BMP-2-Triggered In Vivo Osteo-Organoid. [Abstract]

2023 Aug;10(24):e2301592. PMID: 37357138
Carbohydr Polym

A dermatan sulfate-functionalized biomimetic nanocarrier for melanoma targeted chemotherapy. [Abstract]

2020 May 1;235:115983. PMID: 32122513
Chem Eng J

2026 Feb 12.
J Control Release

Beyond the liver and deeper in the liver: Sub-organ level analysis of in vivo sequestration mechanism of silica nanocapsules. [Abstract]

2026 Jul 10:395:114948. PMID: 42031059
J Control Release

A chemokine "leverage regulation" biomimetic nanoformulation enhances CAR-T cells against solid tumors by reshaping immune cell niches. [Abstract]

2026 Jun 5:396:115064. PMID: 42250608
J Control Release

Bio-orthogonal truncated NKG2D ligand-based nano-igniter unleashes a self-sustaining antitumor immune circuit via NK cell activation. [Abstract]

2026 Mar 10:391:114603. PMID: 41506375
Small

Protein Corona Reprograms Hepatic Clearance Pathways of Biomimetic Nanoparticles via Ligand Masking and Differential Protein Enrichment. [Abstract]

2026 May;22(29):e73301. PMID: 41944292
J Pharm Anal

Reactivating T cell immunity in Wnt-hyperactivated non-small cell lung cancer through a supramolecular droplet of carnosic acid and peptide. [Abstract]

2025 Dec;15(12):101309. PMID: 41492455
Adv Healthc Mater

Physical Encapsulation and Chemotherapy: A Synergistic Hydrogel Strategy for Tumor Suppression. [Abstract]

2025 May 5:e2500511. PMID: 40321022
Nano Today

2025 Oct.
Acta Biomater

Bioprinted dECM particles-laden microgels enhance the mesenchymal stromal cell paracrine effect for myocardial infarction treatment. [Abstract]

2026 Jul:218:350-364. PMID: 42250666
Nano Res

2025 Sep 29.

CY5-SE purchased from MedChemExpress. Usage Cited in: Nano Res. 2025 Sep 29.

Cy5 NHS Ester (2-8 h). Uptake capacity of Cu2–XSe@AHI by damaged HK-2 cells.

CY5-SE purchased from MedChemExpress. Usage Cited in: Nano Res. 2025 Sep 29.

Cy5 NHS Ester (0-8 h). Detection of cellular uptake of Cu2–XSe@AHI by flow cytometry.

CY5-SE purchased from MedChemExpress. Usage Cited in: Nano Res. 2025 Sep 29.

Fluorescence images of renal Cy5 and AQP1 (proximal tubule marker) after Cy5@Cu2–XSe@AHI administration.
Nano Res

29 June 2021.
Small Methods

2026 Feb 27.
Int J Biol Macromol

Structural insights into the binding of nanobodies to the Staphylococcal enterotoxin B. [Abstract]

2024 Jul 17:133957. PMID: 39029852
ACS Appl Mater Interfaces

Surface-Adaptive and Initiator-Loaded Graphene as a Light-Induced Generator with Free Radicals for Drug-Resistant Bacteria Eradication. [Abstract]

2019 Jan 16;11(2):1766-1781. PMID: 30523688
Foods

Lactoferrin-Loaded Liposomal Nanoparticles: Enhanced Intestinal Stability and Bioactivity for Mitigating Radiation-Induced Intestinal Injury. [Abstract]

2025 Oct 2;14(19):3410. PMID: 41097578
Biomacromolecules

A Dual-Interaction Supramolecular Hydrogel System for siRNA Delivery to Enhance Endometrial Receptivity in Stem Cell Therapy. [Abstract]

2025 May 12;26(5):3044-3058. PMID: 40279154
Biomacromolecules

Biodistribution of Filamentous Plant Virus Nanoparticles: Pepino Mosaic Virus versus Potato Virus X. [Abstract]

2019 Jan 14;20(1):469-477. PMID: 30516960
Int Immunopharmacol

Milk exosomes loaded with atorvastatin suppress fibroblast activation and extracellular matrix remodeling via the TGF-β/SMAD pathway in ligamentum flavum hypertrophy. [Abstract]

2026 Apr 1:174:116346. PMID: 41707594
Int J Mol Sci

Human Embryonic Kidney HEK293 Cells as a Model to Study SMVT-Independent Transport of Biotin and Biotin-Furnished Nanoparticles in Targeted Therapy. [Abstract]

2025 Feb 13;26(4):1594. PMID: 40004058
ACS Omega

A LRELHLNNN-Gal‑3 Modified Adipose Decellularized Scaffold To Construct Colorectal Cancer Model for Anticancer Drug Screening and Immunotherapy. [Abstract]

2025 Oct 30;10(44):52931-52943. PMID: 41244442
Molecules

The Importance of Biotinylation for the Suitability of Cationic and Neutral Fourth-Generation Polyamidoamine Dendrimers as Targeted Drug Carriers in the Therapy of Glioma and Liver Cancer. [Abstract]

2024 Sep 10;29(18):4293. PMID: 39339289
Mol Pharm

Regulation of CAF by α-Mangostin Promotes the Penetration of Nanomedicine and Inhibits the Metastasis of Breast Tumor. [Abstract]

2026 Mar 2;23(3):1631-1646. PMID: 41701112
Mol Pharm

Synthesis and Characterization of a Novel PET Tracer for Noninvasive Evaluation of FGL1 Status in Tumors. [Abstract]

2024 Jul 1;21(7):3425-3433. PMID: 38836286
J Virol

VP2 mediates the release of the feline calicivirus RNA genome by puncturing the endosome membrane of infected cells. [Abstract]

2024 May 14;98(5):e0035024. PMID: 38591900
Genomics

Exosomes derived from ovarian cancer cells regulate proliferation and migration of cancer-associated fibroblasts. [Abstract]

2023 Sep;115(5):110703. PMID: 37678440
Bioorg Med Chem

Engineered B7-H3-targeted VHH-Fc fusion antibody demonstrates rapid tumor accumulation for infrared imaging in pancreatic cancer xenograft model. [Abstract]

2025 Nov 1:129:118319. PMID: 40684715
J Appl Biomater Funct Mater

A comparative study of radiation tolerance between dECM hydrogel-adipose composite biomaterials and traditional breast implants. [Abstract]

2025 Jan-Dec:23:22808000251401786. PMID: 41376445
Res Sq

2026 Jun 16.
TransMed

2026 May 15;1(1):100018.
Research Square Preprint

2021 Jan.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (33.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 5.88 mg/mL (7.80 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3265 mL

6.6324 mL

13.2647 mL

5 mM

0.2653 mL

1.3265 mL

2.6529 mL

10 mM

0.1326 mL

0.6632 mL

1.3265 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jeon HY, et al. Array-Based High-Throughput Analysis of Silk-Elastinlike Protein Polymer Degradation and C-Peptide Release by Proteases. Anal Chem. 2016;88(10):5398-5405. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.3265 mL	6.6324 mL	13.2647 mL	33.1618 mL
H₂O / DMSO	5 mM	0.2653 mL	1.3265 mL	2.6529 mL	6.6324 mL
DMSO	10 mM	0.1326 mL	0.6632 mL	1.3265 mL	3.3162 mL
	15 mM	0.0884 mL	0.4422 mL	0.8843 mL	2.2108 mL
	20 mM	0.0663 mL	0.3316 mL	0.6632 mL	1.6581 mL
	25 mM	0.0531 mL	0.2653 mL	0.5306 mL	1.3265 mL
	30 mM	0.0442 mL	0.2211 mL	0.4422 mL	1.1054 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

CY5-SE

45 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CY5-SE

Publications Citing Use of MedChemExpress (MCE) CY5-SE

Biologische Aktivität

Chemical Information

Publications (45)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CY5-SE Related Classifications

HY-D0819 Related Classifications